Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors (Q37401839)
Jump to navigation
Jump to search
scientific article published on 03 December 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors |
scientific article published on 03 December 2010 |
Statements
1 reference
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors (English)
1 reference
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors (English)
1 reference
Eunice L Kwak
1 reference
Jennifer R. Diamond
Geoffrey I. Shapiro
Mark Morrow
1 reference
Jamie Arnott
1 reference
Carolyn Sidor
1 reference
Wells Messersmith
1 reference
Bruno R. Bastos
Ryan J. Hansen
Daniel L. Gustafson
S. Gail Eckhardt
Shuchi S. Pandya
Graham C. Fletcher
Todd M. Pitts
Gillian N. Kulikowski
3 December 2010
1 reference
1 reference
849-860
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference